Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL10535963 | 0.98 | MEN1 (0.33) | MEN1CYP2C9KMT2ALMNAGAA | |
| Water SCHEMBL11060484 | 0.98 | MEN1 (0.33) | MEN1CYP2C9KMT2ALMNAGAA | |
| SCHEMBL7046139 | 0.86 | NPC1 (0.30) | CYP2C9 | |
| SCHEMBL7772327 | 0.77 | LMNA (0.37) | KMT2ALMNAGAACHRNB2SLC6A2 | |
| Water SCHEMBL11125328 | 0.77 | SLC6A2 (0.38) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL136565 | 0.74 | HTR2A (0.41) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9215817 | 0.71 | GRIN1 (0.36) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 | |
| SCHEMBL28570949 | 0.71 | TSHR (0.37) | MEN1CYP2C9KMT2AGAAAKR1C1 | |
| SCHEMBL28411325 | 0.68 | MAPK1 (0.36) | MEN1KMT2ALMNAGAAAKR1C1 | |
| SCHEMBL28760491 | 0.68 | GRIN1 (0.34) | MEN1CYP2C9KMT2AAKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0114567-B1 | 1-CARBONYL-1-PHENYL-2-AZOLYL-ETHANOL DERIVATIVES AS MICROBICIDES AND PLANT GROWTH REGULATORS AND THEIR INTERMEDIATES | CIBA-GEIGY AG (CH) | 1988-09-14 | — | — | EP | claimed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| JP-2004352709-A | METHOD FOR PRODUCING 1-AZOLE-2-PHENYL -2, 3-PROPANEDIOL DERIVATIVE | MITSUI CHEMICALS INC | 2004-12-16 | — | — | JP | disclosed |
| EP-0114567-B1 | 1-CARBONYL-1-PHENYL-2-AZOLYL-ETHANOL DERIVATIVES AS MICROBICIDES AND PLANT GROWTH REGULATORS AND THEIR INTERMEDIATES | CIBA-GEIGY AG (CH) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | MEN1 1677/4885CYP2C9 1373/4885KMT2A 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.